Close Menu

NEW YORK – Precision medicine firm Genetron Health and Chia Tai Tianqing Pharmaceutical Group have entered an exclusive strategic partnership to exclusively  comarket and copromote Genetron's HCCscreen – a blood-based early screening test for liver cancer — in hospitals across designated territories in China.

The parties intend to target high-risk individuals for hepatocellular carcinoma, which include hepatitis B virus carriers, as well as other liver disease patients, using CTTQ's experienced sales force and hospital relationships.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.